Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort database.
Humans
Male
Female
Latent Tuberculosis
/ epidemiology
Precision Medicine
Prospective Studies
Risk Adjustment
Tuberculosis
/ drug therapy
Diabetes Mellitus
Nontuberculous Mycobacteria
Mycobacterium tuberculosis
/ genetics
Liver-Specific Organic Anion Transporter 1
/ genetics
Arylamine N-Acetyltransferase
/ genetics
N-Acetyltransferase-2
Non-tuberculosis mycobacterium
Solute carrier organic anion transporter family member 1B1
The Center for Personalized Precision Medicine of Tuberculosis
Tuberculosis
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
06
02
2023
accepted:
08
09
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
The Center for Personalized Precision Medicine of Tuberculosis (cPMTb) was constructed to develop personalized pharmacotherapeutic systems for tuberculosis (TB). This study aimed to introduce the cPMTb cohort and compare the distinct characteristics of patients with TB, non-tuberculosis mycobacterium (NTM) infection, or latent TB infection (LTBI). We also determined the prevalence and specific traits of polymorphisms in N-acetyltransferase-2 (NAT2) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) phenotypes using this prospective multinational cohort. Until August 2021, 964, 167, and 95 patients with TB, NTM infection, and LTBI, respectively, were included. Clinical, laboratory, and radiographic data were collected. NAT2 and SLCO1B1 phenotypes were classified by genomic DNA analysis. Patients with TB were older, had lower body mass index (BMI), higher diabetes rate, and higher male proportion than patients with LTBI. Patients with NTM infection were older, had lower BMI, lower diabetes rate, higher previous TB history, and higher female proportion than patients with TB. Patients with TB had the lowest albumin levels, and the prevalence of the rapid, intermediate, and slow/ultra-slow acetylator phenotypes were 39.2%, 48.1%, and 12.7%, respectively. The prevalence of rapid, intermediate, and slow/ultra-slow acetylator phenotypes were 42.0%, 44.6%, and 13.3% for NTM infection, and 42.5%, 48.3%, and 9.1% for LTBI, respectively, which did not differ significantly from TB. The prevalence of the normal, intermediate, and lower transporter SLCO1B1 phenotypes in TB, NTM, and LTBI did not differ significantly; 74.9%, 22.7%, and 2.4% in TB; 72.0%, 26.1%, and 1.9% in NTM; and 80.7%, 19.3%, and 0% in LTBI, respectively. Understanding disease characteristics and identifying pharmacokinetic traits are fundamental steps in optimizing treatment. Further longitudinal data are required for personalized precision medicine. This study registered ClinicalTrials.gov NO. NCT05280886.
Sections du résumé
BACKGROUND
BACKGROUND
The Center for Personalized Precision Medicine of Tuberculosis (cPMTb) was constructed to develop personalized pharmacotherapeutic systems for tuberculosis (TB). This study aimed to introduce the cPMTb cohort and compare the distinct characteristics of patients with TB, non-tuberculosis mycobacterium (NTM) infection, or latent TB infection (LTBI). We also determined the prevalence and specific traits of polymorphisms in N-acetyltransferase-2 (NAT2) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) phenotypes using this prospective multinational cohort.
METHODS
METHODS
Until August 2021, 964, 167, and 95 patients with TB, NTM infection, and LTBI, respectively, were included. Clinical, laboratory, and radiographic data were collected. NAT2 and SLCO1B1 phenotypes were classified by genomic DNA analysis.
RESULTS
RESULTS
Patients with TB were older, had lower body mass index (BMI), higher diabetes rate, and higher male proportion than patients with LTBI. Patients with NTM infection were older, had lower BMI, lower diabetes rate, higher previous TB history, and higher female proportion than patients with TB. Patients with TB had the lowest albumin levels, and the prevalence of the rapid, intermediate, and slow/ultra-slow acetylator phenotypes were 39.2%, 48.1%, and 12.7%, respectively. The prevalence of rapid, intermediate, and slow/ultra-slow acetylator phenotypes were 42.0%, 44.6%, and 13.3% for NTM infection, and 42.5%, 48.3%, and 9.1% for LTBI, respectively, which did not differ significantly from TB. The prevalence of the normal, intermediate, and lower transporter SLCO1B1 phenotypes in TB, NTM, and LTBI did not differ significantly; 74.9%, 22.7%, and 2.4% in TB; 72.0%, 26.1%, and 1.9% in NTM; and 80.7%, 19.3%, and 0% in LTBI, respectively.
CONCLUSIONS
CONCLUSIONS
Understanding disease characteristics and identifying pharmacokinetic traits are fundamental steps in optimizing treatment. Further longitudinal data are required for personalized precision medicine.
TRIAL REGISTRATION
BACKGROUND
This study registered ClinicalTrials.gov NO. NCT05280886.
Identifiants
pubmed: 38001469
doi: 10.1186/s12890-023-02646-7
pii: 10.1186/s12890-023-02646-7
pmc: PMC10675857
doi:
Substances chimiques
SLCO1B1 protein, human
0
Liver-Specific Organic Anion Transporter 1
0
NAT2 protein, human
EC 2.3.1.5
Arylamine N-Acetyltransferase
EC 2.3.1.5
Banques de données
ClinicalTrials.gov
['NCT05280886']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
471Informations de copyright
© 2023. The Author(s).
Références
Tuberculosis (Edinb). 2007 Nov;87(6):551-6
pubmed: 17950035
Pharmacogenetics. 1997 Dec;7(6):503-14
pubmed: 9429236
Eur J Clin Pharmacol. 2006 Sep;62(9):727-35
pubmed: 16685561
Clin Infect Dis. 2010 May 15;50 Suppl 3:S184-94
pubmed: 20397947
J Infect Dev Ctries. 2014 Aug 13;8(8):987-93
pubmed: 25116663
Eur J Clin Pharmacol. 2007 Oct;63(10):927-33
pubmed: 17665185
Lancet Diabetes Endocrinol. 2014 Sep;2(9):754-64
pubmed: 25194888
BMC Infect Dis. 2013 Apr 30;13:194
pubmed: 23631563
Clin Infect Dis. 2012 Jul;55(2):169-77
pubmed: 22467670
Br J Clin Pharmacol. 2018 Dec;84(12):2747-2760
pubmed: 30047605
Lancet Infect Dis. 2006 Jul;6(7):438-46
pubmed: 16790384
Int J Tuberc Lung Dis. 2013 Jan;17(1):54-60
pubmed: 23232005
Epidemiol Health. 2018;40:e2018036
pubmed: 30081621
Front Pharmacol. 2020 Jun 05;11:728
pubmed: 32581780
Antimicrob Agents Chemother. 2015 Nov;59(11):6791-9
pubmed: 26282412
Circulation. 2010 Jan 19;121(2):230-6
pubmed: 20038741
Int J Tuberc Lung Dis. 2006 Dec;10(12):1360-6
pubmed: 17167953
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Drugs. 2014 Jun;74(8):839-54
pubmed: 24846578
BMJ Open. 2019 Aug 1;9(8):e027940
pubmed: 31375612
Am J Respir Crit Care Med. 1997 May;155(5):1717-22
pubmed: 9154882
CMAJ. 2011 Feb 22;183(3):E173-9
pubmed: 21220436
PLoS One. 2023 Apr 6;18(4):e0283726
pubmed: 37023111
Front Immunol. 2017 Oct 18;8:1316
pubmed: 29093710
Clin Infect Dis. 2020 Aug 14;71(4):e1-e36
pubmed: 32628747
Eur J Clin Pharmacol. 2007 Jun;63(6):555-63
pubmed: 17415554
Int J Tuberc Lung Dis. 2016 Oct;20(10):1364-1369
pubmed: 27725049
Lancet Infect Dis. 2017 Jan;17(1):39-49
pubmed: 28100438
Arch Toxicol. 2005 Apr;79(4):196-200
pubmed: 15558239
Antimicrob Agents Chemother. 2012 Jun;56(6):3232-8
pubmed: 22411614
Expert Rev Clin Pharmacol. 2017 Jan;10(1):47-58
pubmed: 27724114
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171
pubmed: 20091503
Clin Infect Dis. 2011 May;52(9):e194-9
pubmed: 21467012
Pharmacogenomics. 2018 Jan;19(1):17-29
pubmed: 29210323
Antimicrob Agents Chemother. 2010 Oct;54(10):4192-200
pubmed: 20660695
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1317-1326
pubmed: 34375564
Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7
pubmed: 21709081
J Infect Dis. 2013 Nov 1;208(9):1464-73
pubmed: 23901086
Tuberc Respir Dis (Seoul). 2015 Apr;78(2):56-63
pubmed: 25861337
Br J Clin Pharmacol. 2021 Sep;87(9):3492-3500
pubmed: 33538008
BMC Genet. 2008 Feb 27;9:21
pubmed: 18304320
Clin Infect Dis. 2017 Jan 15;64(2):e1-e33
pubmed: 27932390
J Hum Genet. 2016 Jun;61(6):533-7
pubmed: 26911349
Lancet. 2016 Mar 19;387(10024):1211-26
pubmed: 26377143
Drugs. 2002;62(15):2169-83
pubmed: 12381217
J Infect Dis. 2011 Dec 15;204(12):1951-9
pubmed: 22021624
Br J Clin Pharmacol. 2011 Jul;72(1):51-62
pubmed: 21320152
PLoS One. 2013 Oct 24;8(10):e77979
pubmed: 24205052
Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65
pubmed: 25654354
Int J Urol. 1999 Sep;6(9):446-54
pubmed: 10510890
J Clin Pharmacol. 2021 Dec;61(12):1567-1578
pubmed: 34157153
PLoS One. 2011 Apr 06;6(4):e18507
pubmed: 21494681
Int J Tuberc Lung Dis. 2006 Jun;10(6):696-700
pubmed: 16776459
Eur J Clin Pharmacol. 2013 May;69(5):1091-101
pubmed: 23150149